1	Title: Comparing Machine Learning Algorithms for Predicting ICU
2	Admission and Mortality in COVID-19
3	Authors: Sonu Subudhi ¹ , Ashish Verma ^{2*} , Ankit B. Patel ^{2*} , C. Corey Hardin ³ , Melin J.
4	Khandekar ⁴ , Hang Lee ⁵ , Triantafyllos Stylianopoulos ⁶ , Lance L. Munn ⁷ , Sayon Dutta ^{8#} and
5	Rakesh K. Jain ^{7#}
6	Affiliations:
7	¹ Department of Medicine/Gastroenterology Division, Massachusetts General Hospital and
8	Harvard Medical School, Boston, Massachusetts
9	² Department of Medicine/Renal Division, Brigham and Women's Hospital and Harvard Medical
10	School, Boston, Massachusetts
11	³ Department of Pulmonary and Critical Care Medicine, Massachusetts General Hospital and
12	Harvard Medical School, Boston, Massachusetts
13	⁴ Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical
14	School, Boston, Massachusetts
15	⁵ Biostatistics Center, Massachusetts General Hospital and Harvard Medical School, Boston,
16	Massachusetts
17	⁶ Cancer Biophysics Laboratory, Department of Mechanical and Manufacturing Engineering,
18	University of Cyprus, Nicosia, Cyprus
19	⁷ Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General
20	Hospital and Harvard Medical School, Boston, Massachusetts

⁸Department of Emergency Medicine, Massachusetts General Hospital and Harvard Medical
 School, Boston, Massachusetts

- 23 ^{*}Equal contribution
- [#]To whom correspondence should be addressed: Sayon Dutta, MD (sdutta1@partners.org) and

25 Rakesh K. Jain, PhD (jain@steele.mgh.harvard.edu)

26 Short title: Comparing machine learning algorithms in COVID-19

27

Abstract (150 words): As predicting the trajectory of COVID-19 disease is challenging, 28 machine learning models could assist physicians determine high-risk individuals. This study 29 compares the performance of 18 machine learning algorithms for predicting ICU admission and 30 mortality among COVID-19 patients. Using COVID-19 patient data from the Mass General 31 32 Brigham (MGB) healthcare database, we developed and internally validated models using patients presenting to Emergency Department (ED) between March-April 2020 (n = 1144) and 33 externally validated them using those individuals who encountered ED between May-August 34 35 2020 (n = 334). We show that ensemble-based models perform better than other model types at predicting both 5-day ICU admission and 28-day mortality from COVID-19. CRP, LDH, and 36 procalcitonin levels were important for ICU admission models whereas eGFR <60 37 ml/min/1.73m², ventilator use, and potassium levels were the most important variables for 38 predicting mortality. Implementing such models would help in clinical decision-making for 39 future COVID-19 and other infectious disease outbreaks. 40

- 41 [Main Text: 3422 words]
- 42 Introduction

The COVID-19 pandemic has led to significant morbidity and mortality throughout the world ¹. The rapid spread of SARS-CoV-2 has provided limited time to identify factors involved in SARS-CoV-2 transmission, predictors of COVID-19 severity, and effective treatments. At the height of the pandemic, areas with high number of SARS-CoV-2 infections were resourcelimited and forced to ration life-saving therapies such as ventilators and dialysis machines ^{2,3}. In this setting, being able to identify patients requiring intensive care or at high risk of mortality

upon presentation to the hospital may help providers expedite patients to the most appropriatecare setting.

Model predictions are gaining increasing interest in clinical medicine. Machine learning 51 applications have been used to help predict acute kidney injury ⁴ and septic shock ⁵, amongst 52 other outcomes in hospitalized patients. These tools have also been applied to outpatients to 53 predict outcomes such as heart failure progression⁶. Machine learning tools can be applied to 54 predict outcomes such as Intensive Care Unit (ICU) admission and mortality ⁷. Thus far there 55 have been few studies that examined specific machine learning algorithms in predicting 56 outcomes such as mortality in COVID-19 patients⁸⁻¹⁰. Given the potential utility of machine 57 learning-based decision rules and the urgency of the pandemic, a concerted effort is being made 58 to identify which machine learning applications are optimal for given sets of data and diseases 11 . 59

To address this knowledge gap, we conducted a multi-hospital cohort (Mass General Brigham (MGB) healthcare database) study to extensively evaluate the performance of 18 different machine learning algorithms in predicting ICU admission and mortality. Our goal was to identify the best prognostication algorithm using demographic data, comorbidities, and laboratory findings of COVID-19 patients who visited emergency departments (ED) at MGB between March and April 2020. We validated our models on a temporally distinct patient cohort that

66	tested positive for COVID-19 and had ED encounter between May and August 2020. We also
67	identified critical variables utilized by the model to predict ICU admission and mortality.

68 **Results**

69 Patient characteristics.

We obtained data from 10,826 patients in the multihospital database (Massachusetts 70 General Brigham Healthcare database) who had COVID-19 infection during the period of March 71 72 and April 2020. A total of 3,713 out of the 10,826 patients visited EDs. We evaluated patients based on demographics, medication use, history of past illness, clinical features, and laboratory 73 values described in Table S1. After excluding patients with missing data, 1,144 patients 74 75 remained, 99% of which were in-patients (n = 1133). For external validation, we pulled data of 76 temporally distinct individuals from the Mass General Brigham (MGB) healthcare database who were positive for SARS-CoV-2 between May and August 2020. During this period, 1,754 out of 77 8,013 SARS-CoV-2 positive individuals visited the ER. After excluding patients with missing 78 79 variables from Table S1, a total of 334 patients were left (98% of which were in-patients).

The baseline characteristics of 1,144 patients in the training dataset are listed in Table 1. 80 The overall study population included 45% women, and the majority were above the age of 60. 81 82 The number of patients who were admitted to ICU within 5 days and who died within 28 days of ED visit were 342 (30%) and 217 (19%), respectively. The external validation dataset included 83 patients with similar distribution in age ≥ 50 years ($X^{2}_{(4, N=1193)} = 8.9$, p = 0.063), gender ($X^{2}_{(1, N=1193)} = 8.9$, 84 $_{1478} = 0.017$, p = 0.89), race (X²_(1, N = 1478) = 0.07, p = 0.79) and BMI (X²_(2, N = 1478) = 4.31, p = 0.017) and BMI (X²_(2, N = 1478) = 4.31) 85 0.12) (Table S6). Of the 334 patients who visited the ED, 74 (22%) were admitted to the ICU 86 and 45 (13%) died with COVID-19. 87

88 Comparing performance of prediction models – cross validation.

We evaluated 18 machine learning algorithms belonging to 9 broad categories, namely ensemble, Gaussian process, linear, naïve bayes, nearest neighbor, support vector machine, treebased, discriminant analysis and neural network models.

On comparing the ICU admission prediction models using cross validation, we observed 92 that all ensemble-based models had mean precision-recall area under curve (PR AUC) scores 93 94 more than 0.77 (Table 2; Fig. S2A-B). Specifically, the PR AUC score for AdaBoostClassifier was 0.80 (95% CI, 0.73 - 0.87), for *BaggingClassifier* was 0.80 (95% CI, 0.73 - 0.87), for 95 GradientBoostingClassifier was 0.77 (95% CI, 0.68 – 0.86), for RandomForestClassifier was 96 0.80 (95% CI, 0.70 - 0.90), for XGBClassifier was 0.78 (95% CI, 0.70 - 0.86), and for 97 98 ExtraTreesClassifier was [0.79 (95% CI, 0.72 - 0.86)]. In addition, LogisticRegression [0.79(95% CI, 0.71 – 0.87)], and LinearDiscriminantAnalysis [0.76 (95% CI, 0.68 – 0.84)] also had 99 high PR AUC scores. In contrast, GaussianProcessClassifier [0.6 (95% CI, 0.54 – 0.66)], 100 101 SGDClassifier [0.63 (95% CI, 0.60 - 0.66)] and LinearSVC [0.65 (95% CI, 0.57 - 0.73)] had 102 low PR AUC scores. Upon performing multiple comparison analysis between all models (based 103 on PR AUC and ROC AUC scores), the ensemble-based models and *LogisticRegression* models 104 have similar pattern of performance (Fig. S1A-B). On grouping the models based on their broad 105 categories, we found that ensemble models have significantly higher PR AUC scores than all 106 other model types except for logistic regression (based on Fisher's Least Significant Difference 107 (LSD) t-test; Fig. 2A; details of statistical analysis in Table S7). For ROC AUC scores, ensemble models performed better than all models except logistic regression (Fig. 2A; Table S7). 108

On comparing the mortality prediction models using cross validation, all ensemble-based
 models had mean PR AUC scores higher than 0.8 (Table 3; Fig. S2C-D). The PR AUC score for

111 AdaBoostClassifier was 0.81 (95% CI, 0.76 – 0.86), for BaggingClassifier was 0.81 (95% CI, 0.74 - 0.88), for GradientBoostingClassifier was 0.81 (95% CI, 0.73 - 0.89), for 112 RandomForestClassifier was 0.8 (95% CI, 0.75 – 0.85), for XGBClassifier was 0.82 (95% CI, 113 114 0.75 – 0.89), and ExtraTreesClassifier [0.82 (95% CI, 0.74 – 0.90)]. In addition, LinearDiscriminantAnalysis [0.85 (95% CI, 0.79 – 0.91)] also had a high PR AUC score. 115 However, for mortality prediction, LogisticRegression [0.73 (95% CI, 0.62 - 0.84)] had low PR 116 AUC score when compared to ensemble methods. The lowest PR AUC scores were for 117 GaussianProcessClassifier [0.55 (95% CI, 0.42 – 0.68)], SGDClassifier [0.54 (95% CI, 0.49 – 118 0.59)], Perceptron [0.6 (95% CI, 0.53 - 0.67)], and KNeighborsClassifier [0.6 (95% CI, 0.52 -119 0.68)]. Upon performing multiple comparison analysis between all models (based on PR AUC 120 and ROC AUC scores), the ensemble-based models and LinearDiscriminantAnalysis models had 121 similar patterns of performance (Fig. S1C-D). When we grouped the models based on their broad 122 categories and compared their PR AUC and ROC AUC scores, we found that ensemble-based 123 models perform better than all other model types except Naïve bayes and discriminant analysis 124 based methods (based on Fisher's Least Significant Difference (LSD) t-test; Fig. 2B; details of 125 statistical analysis in Table S7). 126

127 Comparing performance of prediction models – internal and external validation.

We then tested the internal validation dataset on ICU admission models and found that 128 129 ensemble methods (PR AUC \geq 0.8) and LogisticRegression (PR AUC = 0.83) had the best scores 130 (Table 2). However, for the external validation dataset. BaggingClassifier. RandomForestClassifier and XGBClassifier had better PR AUC scores (≥ 0.6) than other 131 ensemble models. LogisticRegression also performed comparably (PR AUC = 0.62) to well-132 performing ensemble methods with the external validation dataset. 133

On evaluating the performance of mortality models using internal validation dataset, ensemble methods, naïve bayes, and discriminant analysis-based models outperformed other models (PR AUC ≥ 0.7) (Table 3). In the external validation dataset, although the PR AUC scores were lower, *AdaBoostClassifier*, *BaggingClassifier*, and *RandomForestClassifier* had better PR AUC scores (≥ 0.37) than other models. Unlike ICU admission prediction, *LogisticRegression* had a low score with internal and external validation datasets (PR AUC = 0.65 and 0.23, respectively).

141 Overall, we found that ensemble models performed well in predicting both ICU142 admission and mortality for COVID-19 patients.

143 Critical variables for predicting ICU admission and mortality.

To investigate how individual variables in the machine learning models impact outcome 144 prediction, we performed SHAP analysis for the best models - namely random forest for the ICU 145 146 admission model and XGB classifier for the mortality prediction model. For the ICU admission prediction models, C-reactive protein, procalcitonin, lactate dehydrogenase, and first respiratory 147 148 rate were directly proportional to risk of ICU admission (Fig. 2C-D), while lower values of the first oxygen saturation reading and lymphocytes were associated with increased probability of 149 150 ICU admission. For mortality prediction models, use of ventilator, estimated glomerular filtration rate less than 60 ml/min/ 1.72 m^2 , age greater than 80 years, hyperkalemia and high procalcitonin 151 were associated with higher mortality while lower lymphocyte counts were associated with 152 increased probability of death (Fig. 2E-F). 153

154 **Discussion**

155 In this study, we evaluated the ability of various machine learning algorithms to predict clinical outcomes such as ICU admission or mortality using data available from initial ER 156 encounter of COVID-19 patients. Based on our analysis of 18 algorithms, we found that 157 ensemble-based methods have moderately better performance than other machine learning 158 algorithms. Optimizing the hyperparameters (Tables S4 and S5) enabled us to achieve the best-159 performing ensemble models. We also identified variables that had the largest impact on the 160 performance of the models. We demonstrated that for predicting ICU admission, C-reactive 161 protein, LDH, procalcitonin, lymphocytes, neutrophils, oxygen saturation and respiratory rate are 162 among the top predictors, but for mortality prediction, $eGFR < 60 \text{ ml/min/}1.73\text{m}^2$, serum 163 potassium levels, use of ventilator, age, ALT and white blood cells are the leading predictors. 164

Our model detected that CRP, LDH, procalcitonin, eGFR< 60 ml/min/m2, serum 165 potassium levels, advanced age and ventilator use are indicative of a worse outcome, which 166 167 aligns with previous studies of ICU admission and mortality (Table S2). Multiple retrospective studies showed that increased procalcitonin values were associated with high risk for severe 168 COVID-19 infection¹². The explanation behind this association is not clear. Increased 169 procalcitonin level in COVID -19 patients can suggest bacterial coinfection, a marker of severity 170 of ARDS and immune dysregulation¹³⁻¹⁵ but may also be a marker of the hyperinflammation 171 associated with COVID-19 severity. We also found reduced kidney function as the major risk 172 factor for ICU mortality. This result has been revealed by two previous studies in the literature, 173 indicating that patients on dialysis and with chronic kidney disease have a high risk of mortality 174 from COVID-19^{16,17}. Our study also highlighted serum potassium level as an important predictor 175 for mortality. This finding has not been reported in the literature to our knowledge, although one 176 study has reported the high prevalence of hypokalemia among patients with COVID-19¹⁸. 177

Potassium derangement is independently associated with increased mortality in ICU patients¹⁹. Deviations in serum potassium levels in COVID-19 patients may suggest dysregulation of the renin-angiotensin system²⁰ which has been suggested to also play a role in SARS-CoV-2 pathogenesis. This finding shows that the model aligns with previously reported clinically relevant markers and also predicts new markers that emerged from our patient population.

Our study utilizes a multi-hospital cohort that has been developed and validated in 183 temporarily distinct subsets of the cohort. Multiple studies in the past using machine learning 184 methodology to study COVID-19 outcomes used only a few machine learning algorithms $^{8-10,21,22}$. 185 However, these studies were oriented toward identifying clinical features rather than determining 186 187 the best machine learning algorithm at predicting clinical outcomes, so only limited number of models were tested. To our knowledge, this is the first study to quantitatively and systematically 188 compare 18 machine learning models through robust methodology encompassing all categories 189 190 of algorithms. We showed that ensemble-methods perform better than other methods in predicting ICU admission and mortality from COVID-19. Ensemble methods are meta-191 algorithms that combine several different machine learning techniques into one unified 192 predictive model (Table S3)²³, which could explain this improvement in performance. We have 193 also done exhaustive hyperparameter tuning to determine the best values. By performing SHAP 194 analysis, we showed how variables impact outcomes in black-box machine learning models. 195 Thus, our study is consistent with previous clinical study results, revealing similar clinical 196 197 predictors for ICU admission and mortality, utilizing higher-performing machine learning 198 models.

199 There are a number of limitations in our study. The lack of complete laboratory values 200 for all patients necessitated exclusion of a large number of patients and removal of some variables in development of the models. As suggested by Jakobsen et al^{24} , imputation is not an advisable method to handle missingness, when the percentage of missing data exceeds 40%. The majority of individuals (>98%) included in our analysis were those patients who visited to ED and subsequently became in-patients. In the patients excluded due to missingness, only ~40% of the patients needed in-patient care. This discrepancy in severity might be the reason for lack of laboratory values in excluded patients.

Another limitation is that, as some of the laboratory values may take hours to be reported, the data may not be available until after the patient has transitioned out of the ER, decreasing the utility of using these predictors in triaging patient disposition. Similarly, as the mortality model uses ventilator use as a predictor, it requires ICU admission to be utilized and would not be valid in an earlier phase of care.

We also observed that the predicting capability on the external cohort (imbalanced 212 dataset) was higher for ICU admission models in comparison to mortality models. This could be 213 214 due to the changes instated in the ICU during the later period of pandemic. The changes in the 215 treatment regimens might be affecting the mortality and thereby affecting the predictive power of 216 our models. Our cohort is based on the population from Southern New England region of United 217 States and includes two hospitals that are world-class academic centers, which could also limit the versatility of the models. More elaborate studies based on this framework in other cohorts 218 219 would help validate our findings.

Our model development process and findings could be used by clinicians in gauging the clinical course, particularly ICU admission, of an individual with COVID-19 during an ED encounter. We would recommend using ensemble-based methods for developing clinical prediction models. Our ensemble methods identified key features in patients, such as kidney

function, potassium, procalcitonin, CRP and LDH, that allowed us to predict clinical outcomes.
 Deploying such models would augment the clinical decision-making process by allowing
 physicians to identify potentially high-risk individuals and adjust their treatment accordingly.

227

- 228 Methods
- 229 Study population

Patients from the Mass General Brigham (MGB) healthcare system that were positive for 230 231 COVID-19 between March and August of 2020 and had an ED encounter were included. Patients either had COVID-19 prior to the index ED visit or were diagnosed during that 232 233 encounter. MGB is an integrated health care system which encompasses 14 hospitals across the 234 New England area in the United States. COVID-19 positive patients were defined by the COVID-19 infection status, a discretely recorded field in the Epic EHR (Epic, Inc., Verona, WI). 235 The COVID-19 infection status was added automatically if a SARS-CoV-2 PCR test was 236 237 positive, or by Infection Control personnel if the patient has a confirmed positive test from an outside facility. This study was approved by the MGB Institutional Review Board. 238

239 Data collection and covariate selection

We queried the data warehouse of our EHR for patient-level data including demographics, comorbidities, home medications, most recent outpatient recorded blood pressure, and death date. For each hospital encounter we extracted vital signs, laboratory values, admitting service, hospital length of stay, date of first ICU admission, amongst others. The patient's problem list was extracted and transformed into a comorbidity matrix by using the "comorbidity" R package ²⁵.

246 **Outcome definition**

The two primary outcomes used for developing the models were ICU admission within 5 days of ED encounter and mortality within 28 days of ED encounter. The beginning of the prediction window began upon arrival to the ED.

250 Model development

As described in Table S1, we selected a reduced set of potential predictor variables from 251 252 previously published literature (Table S2). We used the same covariates in developing the ICU admission and mortality models except for ventilator use which was added to mortality models 253 but excluded from ICU admission models. Age (10 year intervals), race (African American or 254 other), BMI, modified Charlson Comorbidity Index ²⁶, angiotensin converting enzyme 255 256 inhibitor/angiotensin receptor blocker (ACEi/ARB) use, hypertension (>140/90 mmHg), and eGFR <60 ml/min were treated as categorical values. Patients with missing values for the 257 independent variables or obviously incorrect entries (e.g., one patient was listed with respiratory 258 259 rate of 75 breaths per minute) were excluded. Imputation was not advisable due to a high percentage of missingness²⁴. Models were developed using the patients admitted during the 260 period of March and April 2020. For external validation, we used a temporally distinct cohort 261 consisting of patients admitted from May through August 2020. The data set was imbalanced 262 263 with significantly fewer patients who were admitted to the ICU or died due to COVID-19 compared with those who did not. For the purpose of developing and internally validating the 264 machine learning models, we randomly selected surviving patients who were not admitted to the 265 ICU and matched the number of patients who were admitted to the ICU or died (n = 684 for ICU 266 models and n = 434 for mortality models). From this group of patients, 70% (n = 478 for ICU 267

models and n = 303 for mortality models) were used for developing machine learning models and the remaining 30% were used for internal validation.

A total of eighteen machine learning algorithms were tested, the descriptions of which are 270 available in Table S3. For every machine learning model, we used a three-step approach. First, 271 we made models using various combinations of tunable hyperparameters which are used to 272 control the learning process of algorithms. The hyperparameters that were adjusted depended on 273 the algorithm (outlined in Table S4). After developing these models for each combination of 274 hyperparameter, we tested the performance of each of these combinations using a cross 275 validation technique (number of folds = 5) during which a precision-recall area under curve (PR 276 277 AUC) score was considered to select the best hyperparameter (Table S5). PR AUC score compares the positive predictive value (precision) and true positive rate (sensitivity or recall) of a 278 model. For grading the performance of models, we used PR AUC scores as this is more 279 applicable for datasets that are imbalanced. In our case, the external validation dataset remained 280 an imbalanced dataset. 281

282

2 **Evaluation of model performance**

Model performance evaluation was done in three parts. A *StratifiedKFold* technique of cross validation was first used during model development. In this method, 20% of the patients were excluded while training the model and the excluded patients were then used to test the model. This was done in an iterative process. Each model was evaluated by calculating the Receiver Operating Characteristic Area Under the Curve (ROC AUC), PR AUC, F1, recall, precision, balanced accuracy, and Brier scores. To calculate the 95% confidence interval, we used $t_{0.975, df=4} = 2.776$ based on *t*-distribution for n = 5.

For the second level of validation, the model performance was evaluated on the 30% of patients who were not used during development of the models. This cohort worked as an internal validation dataset for these models. Finally, for the external validation, the cohort of patients who presented to the ED between May and August 2020 was used (Table S6).

294 Model interpretation using Shapley values

For explaining the models, SHAP feature importance was reported based on Shapley values ²⁷, details of which are outlined in the Supplementary Methods. SHAP values are useful to explain "black-box" machine learning models which are otherwise difficult to interpret. SHAP values for each patient feature explain the intensity and direction of impact on predicting the outcome.

300 Software

Data cleaning and processing were performed with R (R Core Team, version 3.6.3) using the tidyverse and comorbidity packages ^{25,28,29}. Machine learning model development was done using Python (details in Supplementary Methods) ³⁰⁻³³. The programming code for R and Python are available upon request addressed to the corresponding author (jain@steele.mgh.harvard.edu).

305 Supplementary Materials

306 Methods

307 Fig. S1. Matrix plots showing differential model performance

308 Fig. S2. ROC AUC and PR AUC plots

- 309 Table S1. Selection of patients and variable details used for developing and testing the models
- Table S2. Risk factors identified for mortality and ICU admission in COVID-19 studies
- 311 Table S3. Description of machine learning algorithms
- Table S4. Hyperparameters which were optimized for machine learning algorithms
- Table S5. Best hyperparameter values for machine learning algorithms that were chosen after
- tuning hyperparameters using *GridSearchCV* and *cross validation* technique.
- Table S6. Characteristics of patients who visited the emergency room between May and August
- 316 2020 for COVID-19, that were used to evaluate the machine learning models as an external
- 317 dataset. Variables stratified based on ICU admission and death of patients.
- Table S7. Multiple comparison between ensemble methods and other types of machine learning
- algorithms using Fischer Least Significant Difference (LSD) t-test.

320 **References:**

- 321 1 WorldHealthOrganization. Coronavirus disease (COVID-19): situation report, 182. (2020).
- 2 Antommaria, A. H. M. *et al.* Ventilator Triage Policies During the COVID-19 Pandemic at U.S. Hospitals
- 323 Associated With Members of the Association of Bioethics Program Directors. Ann Intern Med 173, 188-
- 324 194, doi:10.7326/m20-1738 (2020).
- 325 3 Silberzweig, J. *et al.* Rationing Scarce Resources: The Potential Impact of COVID-19 on Patients with
- 326 Chronic Kidney Disease. *Journal of the American Society of Nephrology* **31**, 1926,
- 327 doi:10.1681/ASN.2020050704 (2020).

- 328 4 Tomasev, N. *et al.* A clinically applicable approach to continuous prediction of future acute kidney injury.
- 329 *Nature* **572**, 116-119, doi:10.1038/s41586-019-1390-1 (2019).
- 330 5 Henry, K. E., Hager, D. N., Pronovost, P. J. & Saria, S. A targeted real-time early warning score
- 331 (TREWScore) for septic shock. *Sci Transl Med* **7**, 299ra122, doi:10.1126/scitranslmed.aab3719 (2015).
- 332 6 Wehbe, R. M., Khan, S. S., Shah, S. J. & Ahmad, F. S. Predicting High-Risk Patients and High-Risk
- 333 Outcomes in Heart Failure. *Heart Fail Clin* **16**, 387-407, doi:10.1016/j.hfc.2020.05.002 (2020).
- 334 7 Subudhi, S., Verma, A. & B.Patel, A. Prognostic machine learning models for COVID-19 to facilitate
- decision making. *International Journal of Clinical Practice*, e13685, doi:10.1111/ijcp.13685 (2020).
- 336 8 Yan, L. *et al.* An interpretable mortality prediction model for COVID-19 patients. *Nature Machine*
- 337 *Intelligence* **2**, 283-288, doi:10.1038/s42256-020-0180-7 (2020).
- Iwendi, C. *et al.* COVID-19 Patient Health Prediction Using Boosted Random Forest Algorithm. *Front Public Health* 8, 357, doi:10.3389/fpubh.2020.00357 (2020).
- 34010Wu, G. *et al.* Development of a clinical decision support system for severity risk prediction and triage of
- 341 COVID-19 patients at hospital admission: an international multicentre study. *Eur Respir J* 56,
- 342 doi:10.1183/13993003.01104-2020 (2020).
- Eaneff, S., Obermeyer, Z. & Butte, A. J. The Case for Algorithmic Stewardship for Artificial Intelligence
 and Machine Learning Technologies. *JAMA*, doi:10.1001/jama.2020.9371 (2020).
- Lippi, G. & Plebani, M. Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): A
 meta-analysis. *Clin Chim Acta* 505, 190-191, doi:10.1016/j.cca.2020.03.004 (2020).
- Linscheid, P. *et al.* In vitro and in vivo calcitonin I gene expression in parenchymal cells: a novel product
 of human adipose tissue. *Endocrinology* 144, 5578-5584, doi:10.1210/en.2003-0854 (2003).
- 349 14 Muller, B. *et al.* Ubiquitous expression of the calcitonin-i gene in multiple tissues in response to sepsis. J
- 350 *Clin Endocrinol Metab* **86**, 396-404, doi:10.1210/jcem.86.1.7089 (2001).
- 351 15 Meisner, M. Update on procalcitonin measurements. Ann Lab Med 34, 263-273,
- doi:10.3343/alm.2014.34.4.263 (2014).
- Williamson, E. J. *et al.* Factors associated with COVID-19-related death using OpenSAFELY. *Nature* 584,
 430-436, doi:10.1038/s41586-020-2521-4 (2020).

- 355 17 Flythe, J. E. et al. Characteristics and Outcomes of Individuals With Pre-existing Kidney Disease and
- 356 COVID-19 Admitted to Intensive Care Units in the United States. Am J Kidney Dis,
- 357 doi:10.1053/j.ajkd.2020.09.003 (2020).
- 358 18 Chen, D. et al. Assessment of Hypokalemia and Clinical Characteristics in Patients With Coronavirus
- 359 Disease 2019 in Wenzhou, China. JAMA Netw Open 3, e2011122,
- 360 doi:10.1001/jamanetworkopen.2020.11122 (2020).
- 19 Hessels, L. *et al.* The relationship between serum potassium, potassium variability and in-hospital mortality
- in critically ill patients and a before-after analysis on the impact of computer-assisted potassium control.
- 363 *Crit Care* **19**, 4, doi:10.1186/s13054-014-0720-9 (2015).
- 20 Weir, M. R. & Rolfe, M. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors. *Clin*
- 365 *J Am Soc Nephrol* **5**, 531-548, doi:10.2215/CJN.07821109 (2010).
- 36621Yao, H. *et al.* Severity Detection for the Coronavirus Disease 2019 (COVID-19) Patients Using a Machine
- 367 Learning Model Based on the Blood and Urine Tests. *Front Cell Dev Biol* **8**, 683,
- 368 doi:10.3389/fcell.2020.00683 (2020).
- Liang, W. *et al.* Early triage of critically ill COVID-19 patients using deep learning. *Nat Commun* 11, 3543,
 doi:10.1038/s41467-020-17280-8 (2020).
- 371 23 Dietterich, T. G. in *Proceedings of the First International Workshop on Multiple Classifier Systems* 1–15
 372 (Springer-Verlag, 2000).
- 373 24 Jakobsen, J. C., Gluud, C., Wetterslev, J. & Winkel, P. When and how should multiple imputation be used
- for handling missing data in randomised clinical trials a practical guide with flowcharts. BMC Med Res
- 375 *Methodol* **17**, 162, doi:10.1186/s12874-017-0442-1 (2017).
- Gasparini, A. comorbidity: An R package for computing comorbidity scores. *Journal of Open Source Software* 3, 648, doi:10.21105/joss.00648 (2018).
- 26 Charlson, M. E., Pompei, P., Ales, K. L. & MacKenzie, C. R. A new method of classifying prognostic
- 379 comorbidity in longitudinal studies: development and validation. *J Chronic Dis* **40**, 373-383,
- 380 doi:10.1016/0021-9681(87)90171-8 (1987).
- 27 Lundberg, S. M. & Lee, S.-I. A Unified Approach to Interpreting Model Predictions. 4765--4774 (2017).

382	28	R_Core_Team. R: A Language and Environment for Statistical Computing, < <u>https://www.R-project.org/</u> >
383		(2020).
384	29	Wickham, H. et al. Welcome to the Tidyverse. Journal of Open Source Software 4, 1686,
385		doi:10.21105/joss.01686 (2019).
386	30	Pedregosa, F. et al. Scikit-learn: Machine Learning in Python. Journal of Machine Learning Research 12
387		(2012).
388	31	Harris, C. R. et al. Array programming with NumPy. Nature 585, 357-362, doi:10.1038/s41586-020-2649-
389		2 (2020).
390	32	Chen, T. & Guestrin, C. XGBoost: A Scalable Tree Boosting System. (2016).
391	33	McKinney, W. pandas: a Foundational Python Library for Data Analysis and Statistics. Python High
392		Performance Science Computer (2011).
393		
394		
395	Ackn	owledgments: Rakesh Jain's research is supported by R01-CA208205, and U01-CA
396		224348, Outstanding Investigator Award R35-CA197743 and grants from the National
397		Foundation for Cancer Research, Jane's Trust Foundation, American Medical Research
308		Foundation and Harvard Ludwig Cancer Center. We would like to thank Ashwir

395	Acknowledgments: Rakesh Jain's research is supported by R01-CA208205, and U01-CA
396	224348, Outstanding Investigator Award R35-CA197743 and grants from the National
397	Foundation for Cancer Research, Jane's Trust Foundation, American Medical Research
398	Foundation and Harvard Ludwig Cancer Center. We would like to thank Ashwin
399	Srinivasan Kumar, Avanish Ranjan, Tariq Anwar and Mushtaq Rizvi for advice on
400	machine learning algorithms and Python coding. Author contributions: S.S. performed,
401	designed and built machine learning models. S.D. extracted data from the MGB database.
402	A.V., A.B.P., C.C.H., M.J.K., S.D., H.L., T.S., L.L.M., and R.K.J supervised model
403	development. All authors were involved in writing the article. Competing interests:
404	LLM owns equity in Bayer AG and is a consultant for SimBiosys. R.K.J. received
405	honorarium from Amgen; consultant fees from Chugai, Merck, Ophthotech, Pfizer,
406	SPARC, SynDevRx, XTuit; owns equity in Accurius, Enlight, Ophthotech, SynDevRx;

and serves on the Boards of Trustees of Tekla Healthcare Investors, Tekla Life Sciences 407 Investors, Tekla Healthcare Opportunities Fund, Tekla World Healthcare Fund. Neither 408 any reagent nor any funding from these organizations was used in this study. Other 409 coauthors have no conflict of interests to declare. Data and materials availability: The 410 programming code for R and Python are available upon request addressed to the 411 412 corresponding author (jain@steele.mgh.harvard.edu). 413 414 **Figures legends**: 415 416 Fig. 1. Schematic diagram representing the process of machine learning model development. (A) 417 Flow diagram depicting steps in obtaining the training and external validation datasets 418 (with patient numbers in each step). (B) The process of patient selection, dataset 419 420 balancing, hyperparameter tuning, cross-validation, internal and external validation are shown. 421 422 Fig. 2. (A-B). Boxplots representing the precision recall area under the curve (PR AUC) and 423 424 receiver operating characteristic area under the curve (ROC AUC) scores of ICU admission and mortality prediction models. Error bars indicate minimum and maximum 425 426 values. Statistical analysis was performed using Fisher's Least Significant Difference 427 (LSD) t-test. p-value style is geometric progression - <0.03 (*), <0.002 (**), <0.002(***), <0.0001 (****). Variables of importance for ICU admission and mortality 428 prediction models. (C) SHAP value summary dot plot and (D) variable of importance of 429 430 RandomForest algorithm-based ICU admission model. (E) SHAP value summary dot

plot and (F) variable of importance of XGBClassifier algorithm-based mortality model. 431 The calculation of SHAP values is done by comparing the prediction of the model with 432 and without the feature in every possible way of adding the feature to the model. The bar 433 plot depicts the mean SHAP values whereas the summary dot plot shows the impact on 434 the model. The color of the dot represents the value of the feature and the X-axis depicts 435 the direction and magnitude of the impact. Red colored dots represent high value of the 436 feature and the blue represents lower value. A positive SHAP value means the feature 437 value increases likelihood of ICU admission/mortality. For features with positive SHAP 438 value for red dots, suggests directly proportional variable to outcome of interest and those 439 with positive SHAP value correlation. for blue dots. suggest inverse 440

441 **Table 1.** Characteristics of patients who visited emergency department during March and April 2020 for COVID-19, that were

442	included for building the machine learning models.	Variables stratified based on ICU admission and death of pat	tients.

		ICU admission Death						
	Overall	No	Yes	р	No	Yes	р	
n	1144	802	342	0	927	217	0	
Demographics								
Age group (%)				< 0.001			< 0.001	
10-19	1 (0.1)	1 (0.1)	0 (0.0)	0	1 (0.1)	0 (0.0)	0	
20-29	26 (2.3)	19 (2.4)	7 (2.0)	0	26 (2.8)	0 (0.0)	0	
30-39	71 (6.2)	53 (6.6)	18 (5.3)	0	70 (7.6)	1 (0.5)	0	
40-49	113 (9.9)	80 (10.0)	33 (9.6)	0	108 (11.7)	5 (2.3)	0	
50-59	196 (17.1)	131 (16.3)	65 (19.0)	0	180 (19.4)	16 (7.4)	0	
60-69	223 (19.5)	131 (16.3)	92 (26.9)	0	200 (21.6)	23 (10.6)	0	
70-79	231 (20.2)	158 (19.7)	73 (21.3)	0	169 (18.2)	62 (28.6)	0	
80-89	201 (17.6)	152 (19.0)	49 (14.3)	0	126 (13.6)	75 (34.6)	0	
90+	82 (7.2)	77 (9.6)	5 (1.5)	0	47 (5.1)	35 (16.1)	0	
Sex = Male (%)	629 (55.0)	402 (50.1)	227 (66.4)	< 0.001	502 (54.2)	127 (58.5)	0.276	
Race = Other (%)	949 (83.0)	675 (84.2)	274 (80.1)	0.114	772 (83.3)	177 (81.6)	0.615	
BMI_categorical (%)				0.005			0.001	
[0,25]	285 (24.9)	220 (27.4)	65 (19.0)	0	209 (22.5)	76 (35.0)	0	
(25,30]	387 (33.8)	270 (33.7)	117 (34.2)	0	326 (35.2)	61 (28.1)	0	
(30,75]	472 (41.3)	312 (38.9)	160 (46.8)	0	392 (42.3)	80 (36.9)	0	
Medication use								
On ACEi/ARB = TRUE (%)	288 (25.2)	190 (23.7)	98 (28.7)	0.09	232 (25.0)	56 (25.8)	0.88	
On ARA = TRUE (%)	26 (2.3)	16 (2.0)	10 (2.9)	0.454	17 (1.8)	9(4.1)	0.071	
On Calcium channel blocker = TRUE (%)	220 (19.2)	157 (19.6)	63 (18.4)	0.71	163 (17.6)	57 (26.3)	0.005	
On Betablocker = TRUE (%)	285 (24.9)	208 (25.9)	77 (22.5)	0.25	195 (21.0)	90 (41.5)	<0.001	
On Vasodilator = TRUE (%)	80 (7.0)	64 (8.0)	16 (4.7)	0.06	54 (5.8)	26 (12.0)	0.002	
On Alphablocker = TRUE (%)	19 (1.7)	16 (2.0)	3 (0.9)	0.271	16 (1.7)	3 (1.4)	0.951	
On Diuretic = TRUE (%)	250 (21.9)	187 (23.3)	63 (18.4)	0.079	174 (18.8)	76 (35.0)	< 0.001	
On Antiplatelet = TRUE (%)	35 (3.1)	26 (3.2)	9 (2.6)	0.718	28 (3.0)	7 (3.2)	1	
On NSAIDs = TRUE (%)	126 (11.0)	84 (10.5)	42 (12.3)	0.429	113 (12.2)	13 (6.0)	0.012	
On Proton pump inhibitor = TRUE (%)	275 (24.0)	191 (23.8)	84 (24.6)	0.846	206 (22.2)	69 (31.8)	0.004	
On Statin = TRUE (%)	456 (39.9)	326 (40.6)	130 (38.0)	0.443	332 (35.8)	124 (57.1)	<0.001	
On Anticoagulant = TRUE (%)	133 (11.6)	93 (11.6)	40 (11.7)	1	84 (9.1)	49 (22.6)	<0.001	
History of past illness								
Acute myocardial infarction = 1 (%)	33 (2.9)	25 (3.1)	8 (2.3)	0.598	21 (2.3)	12 (5.5)	0.018	
Congestive heart failure = 1 (%)	136 (11.9)	107 (13.3)	29 (8.5)	0.026	79 (8.5)	57 (26.3)	< 0.001	
Peripheral vascular disease = 1 (%)	78 (6.8)	58 (7.2)	20 (5.8)	0.47	51 (5.5)	27 (12.4)	< 0.001	
Cerebrovascular disease = 1 (%)	109 (9.5)	81 (10.1)	28 (8.2)	0.369	65 (7.0)	44 (20.3)	<0.001	
Dementia = 1 (%)	78 (6.8)	67 (8.4)	11 (3.2)	0.002	43 (4.6)	35 (16.1)	< 0.001	
Chronic obstructive pulmonary disease = 1 (%)	167 (14.6)	132 (16.5)	35 (10.2)	0.008	118 (12.7)	49 (22.6)	< 0.001	
Rheumatic disease = 1 (%)	31 (2.7)	21 (2.6)	10 (2.9)	0.926	22 (2.4)	9 (4.1)	0.224	
Peptic ulcer disease = 1 (%)	16 (1.4)	13 (1.6)	3 (0.9)	0.48	11 (1.2)	5 (2.3)	0.347	
Mild liver disease = 1 (%)	70 (6.1)	49 (6.1)	21 (6.1)	1	54 (5.8)	16 (7.4)	0.484	

Diabetes = 1 (%)	257 (22.5)	169 (21.1)	88 (25.7)	0.099	189 (20.4)	68 (31.3)	0.001
Diabetes with complications = 1 (%)	113 (9.9)	81 (10.1)	32 (9.4)	0.781	77 (8.3)	36 (16.6)	<0.001
Hemiplegia = 1 (%)	12 (1.0)	7 (0.9)	5 (1.5)	0.563	9 (1.0)	3 (1.4)	0.868
Renal disease = 1 (%)	180 (15.7)	136 (17.0)	44 (12.9)	0.099	104 (11.2)	76 (35.0)	<0.001
Cancer = 1 (%)	133 (11.6)	100 (12.5)	33 (9.6)	0.207	89 (9.6)	44 (20.3)	< 0.001
Moderate/severe liver disease = 1 (%)	9 (0.8)	5 (0.6)	4 (1.2)	0.554	6 (0.6)	3 (1.4)	0.499
Metastatic cancer = 1 (%)	14 (1.2)	11 (1.4)	3 (0.9)	0.687	7 (0.8)	7 (3.2)	0.008
AIDS = 1 (%)	9 (0.8)	8 (1.0)	1 (0.3)	0.384	6 (0.6)	3 (1.4)	0.499
Hypertension = 1 (%)	464 (40.6)	318 (39.7)	146 (42.7)	0.372	372 (40.1)	92 (42.4)	0.592
Laboratory values and clinical examination							
CRP (mg/L) (mean (SD))	97.74 (82.36)	76.50 (68.54)	147.54 (90.31)	<0.001	91.98 (80.07)	122.35 (87.53)	<0.001
First respiratory rate (counts/min) (mean (SD))	24.23 (7.19)	22.78 (5.85)	27.63 (8.74)	<0.001	23.71 (6.67)	26.45 (8.76)	<0.001
	. ,		101.41			. ,	
First heart rate (beats/min) (mean (SD))	95.44 (19.67)	92.89 (18.87)	(20.22)	<0.001	96.03 (19.24)	92.89 (21.28)	0.034
Sodium (mmol/L) (mean (SD))	137.36 (5.56)	137.68 (5.09)	136.61 (6.48)	0.003	136.99 (5.05)	138.94 (7.14)	<0.001
Calcium (mg/dL) (mean (SD))	8.98 (0.59)	9.03 (0.59)	8.86 (0.59)	<0.001	8.98 (0.58)	8.95 (0.64)	0.46
Magnesium (mg/dL) (mean (SD))	2.03 (0.33)	2.01 (0.31)	2.08 (0.38)	0.003	2.01 (0.32)	2.11 (0.36)	<0.001
Potassium (mmol/L) (mean (SD))	4.11 (0.59)	4.10 (0.57)	4.12 (0.65)	0.604	4.04 (0.54)	4.37 (0.72)	<0.001
Chloride (mmol/L) (mean (SD))	98.46 (5.95)	98.88 (5.50)	97.48 (6.78)	<0.001	98.09 (5.55)	100.03 (7.22)	<0.001
Lymphocytes (percentage; ref = 22-44%) (mean (SD))	16.60 (10.17)	17.87 (10.20)	13.61 (9.47)	<0.001	17.20 (9.67)	14.02 (11.76)	<0.001
Neutrophils (percentage; ref = 40-70%) (mean (SD))	73.30 (12.14)	71.65 (12.16)	77.17 (11.20)	<0.001	72.80 (11.60)	75.43 (14.04)	0.004
WBC (x1000/µL) (mean (SD))	7.61 (6.15)	7.19 (5.63)	8.60 (7.15)	< 0.001	7.41 (5.43)	8.48 (8.55)	0.02
	1923.26	1749.62	2330.43	0.01	1779.02	2539.41	0.004
D-dimer (ng/mL) (mean (SD))	(3473.28)	(2383.80)	(5181.81)	0.01	(3526.78)	(3169.14)	0.004
Total bilirubin (mg/dL) (mean (SD))	0.58 (0.89)	0.56 (1.02)	0.62 (0.43)	0.322	0.57 (0.96)	0.62 (0.49)	0.45
Ferritin (μg/L) (mean (SD))	935.85 (2071.69)	738.57 (1066.99)	1398.46 (3377.22)	<0.001	829.81 (1167.77)	1388.82 (4075.61)	<0.001
LDH (Units) (mean (SD))	370.12 (517.90)	321.17 (273.25)	484.93 (839.54)	<0.001	348.47 (271.12)	462.65 (1045.77)	0.003
Low GFR (<60 ml/min/1.73m2) = TRUE (%)	454 (39.7)	317 (39.5)	137 (40.1)	0.918	300 (32.4)	154 (71.0)	< 0.001
Anion gap (mmol/L) (mean (SD))	15.71 (3.49)	15.24 (3.16)	16.81 (3.96)	<0.001	15.52 (3.31)	16.54 (4.08)	< 0.001
Hemoglobin (g/dL) (mean (SD))	12.99 (2.09)	12.84 (2.06)	13.32 (2.12)	<0.001	13.10 (1.98)	12.52 (2.47)	<0.001
First O2 saturation (%) (mean (SD))	93.81 (6.22)	94.93 (4.66)	91.17 (8.30)	< 0.001	94.06 (6.16)	92.71 (6.40)	0.004
ventilator use = TRUE (%)	294 (25.7)	NA	NA	NA	195 (21.0)	99 (45.6)	< 0.001
Procalcitonin (ng/ml) (mean (SD))	1.11 (5.98)	0.63 (3.56)	2.23 (9.40)	< 0.001	0.73 (3.99)	2.73 (10.86)	< 0.001
	153.76	146.45	170.91	<0.001	151.32	164.19	0.033
Glucose (mg/dL) (mean (SD))	(80.04)	(70.68)	(96.53)		(78.94)	(83.96)	
ALT (IU/L) (mean (SD))	45.05 (202.49)	35.68 (36.49)	67.02 (365.53)	0.016	40.73 (39.82)	63.50 (457.98)	0.136

443 Table 2. Performance of machine learning models to predict ICU admission within 5 days in COVID-19 patients. Cross-validation

444 scores are expressed as mean \pm 95% confidence interval.

Method Type	Model Name	Dataset	ROC AUC	PR AUC	F1 score	Recall	Precision	Balanced	Brier	Total
-------------	------------	---------	---------	--------	----------	--------	-----------	----------	-------	-------

								accuracy	score	positive events
Ensemble	AdaBoostClassifier	Cross-validation	0.79 ± 0.06	0.8 ± 0.07	0.74 ± 0.04	0.74 ± 0.03	0.74 ± 0.06	0.73 ± 0.05	0.23 ± 0.0	244/478
		Internal validation	0.8	0.81	0.67	0.63	0.72	0.71	0.23	98/206
		External validation	0.76	0.54	0.53	0.62	0.46	0.71	0.23	74/334
	BaggingClassifier	Cross-validation	0.8 ± 0.04	0.8 ± 0.07	0.73 ± 0.06	0.71 ± 0.07	0.76 ± 0.06	0.73 ± 0.05	0.2 ± 0.01	244/478
		Internal validation	0.81	0.81	0.73	0.69	0.77	0.75	0.2	98/206
		External validation	0.79	0.61	0.54	0.62	0.48	0.72	0.18	74/334
	GradientBoostingCla	Cross-validation	0.77 ± 0.07	0.77 ± 0.09	0.73 ± 0.07	0.73 ± 0.1	0.73 ± 0.06	0.72 ± 0.06	0.2 ± 0.04	244/478
	ssifier	Internal validation	0.8	0.8	0.7	0.66	0.73	0.72	0.19	98/206
		External validation	0.77	0.57	0.52	0.66	0.43	0.7	0.19	74/334
	RandomForestClass	Cross-validation	0.79 ± 0.06	0.8 ± 0.1	0.74 ± 0.06	0.73 ± 0.06	0.76 ± 0.07	0.74 ± 0.07	0.19 ± 0.02	244/478
	ifier	Internal validation	0.8	0.82	0.72	0.67	0.77	0.74	0.18	98/206
		External validation	0.81	0.62	0.56	0.66	0.49	0.73	0.16	74/334
	XGBClassifier	Cross-validation	0.78 ± 0.06	0.78 ± 0.08	0.73 ± 0.04	0.72 ± 0.05	0.74 ± 0.04	0.72 ± 0.04	0.2 ± 0.03	244/478
		Internal validation	0.81	0.81	0.7	0.66	0.74	0.73	0.18	98/206
		External validation	0.77	0.6	0.51	0.59	0.45	0.69	0.17	74/334
	ExtraTreesClassifier	Cross-validation	0.79 ± 0.04	0.79 ± 0.07	0.72 ± 0.06	0.71 ± 0.08	0.73 ± 0.04	0.72 ± 0.05	0.19 ± 0.01	244/478
		Internal validation	0.79	0.8	0.67	0.65	0.7	0.7	0.19	98/206
		External validation	0.75	0.54	0.49	0.64	0.39	0.68	0.19	74/334
Gaussian	GaussianProcessCl	Cross-validation	0.63 ± 0.06	0.6 ± 0.06	0.55 ± 0.07	0.48 ± 0.05	0.64 ± 0.1	0.59 ± 0.07	0.25 ± 0.0	244/478
process	assifier	Internal validation	0.58	0.5	0.48	0.45	0.52	0.54	0.25	98/206
•		External validation	0.65	0.29	0.31	0.34	0.29	0.55	0.25	74/334
Linear	LogisticRegression	Cross-validation	0.77 ± 0.07	0.79 ± 0.08	0.71 ± 0.04	0.69 ± 0.05	0.73 ± 0.05	0.71 ± 0.05	0.19 ± 0.03	244/478
models		Internal validation	0.83	0.83	0.73	0.7	0.77	0.75	0.17	98/206
		External validation	0.81	0.62	0.58	0.64	0.53	0.74	0.16	74/334
	PassiveAggressiveC	Cross-validation	0.67 ± 0.1	0.7 ± 0.09	0.49 ± 0.32	0.59 ± 0.48	0.69 ± 0.3	0.53 ± 0.09	0.28 ± 0.06	244/478
	lassifier	Internal validation	0.77	0.77	0.1	0.05	1	0.53	0.34	98/206
		External validation	0.73	0.46	0.17	0.09	0.78	0.54	0.16	74/334
	SGDClassifier	Cross-validation	0.68 ± 0.03	0.63 ± 0.03	0.69 ± 0.04	0.69 ± 0.05	0.69 ± 0.03	0.68 ± 0.03	0.32 ± 0.03	244/478
		Internal validation	0.72	0.65	0.69	0.63	0.76	0.72	0.27	98/206
		External validation	0.7	0.39	0.53	0.54	0.53	0.7	0.21	74/334
	Perceptron	Cross-validation	0.71 ± 0.06	0.72 ± 0.05	0.37 ± 0.39	0.39 ± 0.54	0.78 ± 0.22	0.57 ± 0.1	0.32 ± 0.11	244/478
	reception	Internal validation	0.71	0.72	0.64	0.99	0.47	0.49	0.31	98/206
		External validation	0.58	0.35	0.36	0.97	0.22	0.49	0.57	74/334
Naïve Bayes	GaussianNB	Cross-validation	0.72 ± 0.03	0.00	0.57 ± 0.09	0.07 ± 0.12	0.22 0.74 ± 0.06	0.43 0.65 ± 0.04	0.34 ± 0.03	244/478
Nulve Buyes	Caussianin	Internal validation	0.75	0.74	0.58	0.46	0.8	0.68	0.3	98/206
		External validation	0.71	0.46	0.48	0.5	0.46	0.67	0.22	74/334
Nearest	KNeighborsClassifie	Cross-validation	0.67 ± 0.06	0.40 0.68 ± 0.07	0.62 ± 0.04	0.58 ± 0.05	0.66 ± 0.06	0.63 ± 0.05	0.22 ± 0.01	244/478
Neighbor	r	Internal validation	0.71	0.00 ± 0.07	0.66	0.68	0.64	0.05 ± 0.05	0.23 ± 0.01	98/206
Neighbol	1	External validation	0.69	0.45	0.00	0.59	0.35	0.64	0.22	74/334
Support	LinearSVC	Cross-validation	0.09 0.59 ± 0.1	0.43 0.65 ± 0.08	0.39 ± 0.36	0.39 0.46 ± 0.56	0.35 0.67 ± 0.29	0.04 0.52 ± 0.08	0.2 0.33 ± 0.07	244/478
vector	Linearovo	Internal validation	0.63	0.65 ± 0.08 0.58	0.39 ± 0.36 0.02	0.48 ± 0.58 0.01	0.07 ± 0.29	0.52 ± 0.08	0.33 ± 0.07	98/206
machine		External validation	0.67	0.38	0.02	0.01	1	0.51	0.21	74/334
Tree based	DecisionTreeClassifi	Cross-validation	0.67 0.66 ± 0.08	0.38 0.67 ± 0.09	0.05 0.62 ± 0.1	0.03 0.61 ± 0.12	0.63 ± 0.08	0.51 0.62 ± 0.08	0.21 0.27 ± 0.04	244/478
nee based			0.60 ± 0.08	0.67 ± 0.09 0.64	0.62 ± 0.1	0.61 ± 0.12 0.53	0.03 ± 0.08 0.6	0.62 ± 0.08	0.27 ± 0.04 0.25	244/478 98/206
	er	Internal validation		0.64	0.57			0.61	0.25	98/206 74/334
Disoriminant	LincorDiscriminant	External validation	0.68	-	-	0.55	0.34		-	
Discriminant	LinearDiscriminantA	Cross-validation	0.74 ± 0.05	0.76 ± 0.08	0.69 ± 0.05	0.68 ± 0.07	0.71 ± 0.04	0.69 ± 0.04	0.22 ± 0.03	244/478
analysis	nalysis	Internal validation	0.74	0.74	0.65	0.67	0.63	0.66	0.22	98/206
		External validation	0.71	0.5	0.46	0.57	0.39	0.66	0.2	74/334

	QuadraticDiscrimina	Cross-validation	0.72 ± 0.03	0.69 ± 0.03	0.74 ± 0.04	0.87 ± 0.06	0.64 ± 0.03	0.68 ± 0.04	0.31 ± 0.04	244/478
	ntAnalysis	Internal validation	0.79	0.74	0.71	0.86	0.61	0.68	0.31	98/206
		External validation	0.79	0.48	0.48	0.88	0.33	0.68	0.41	74/334
Neural	MLPClassifier	Cross-validation	0.72 ± 0.05	0.72 ± 0.05	0.7 ± 0.05	0.78 ± 0.16	0.65 ± 0.1	0.65 ± 0.11	0.22 ± 0.03	244/478
network		Internal validation	0.77	0.78	0.68	0.63	0.73	0.71	0.19	98/206
		External validation	0.75	0.58	0.53	0.65	0.44	0.71	0.18	74/334

445 **Table 3.** Performance of machine learning models to predict mortality within 28 days in COVID-19 patients. Cross-validation scores

446 are expressed as mean \pm 95% confidence interval.

Method Type	Model Name	Dataset	ROC AUC	PR AUC	F1 score	Recall	Precision	Balanced accuracy	Brier score	Total positive events
Ensemble	AdaBoostClassifier	Cross-validation	0.82 ± 0.05	0.81 ± 0.05	0.73 ± 0.06	0.73 ± 0.09	0.73 ± 0.07	0.73 ± 0.06	0.23 ± 0.0	154/303
		Internal validation	0.79	0.75	0.69	0.68	0.7	0.71	0.24	63/131
		External validation	0.78	0.38	0.42	0.71	0.3	0.73	0.23	45/334
	BaggingClassifier	Cross-validation	0.82 ± 0.03	0.81 ± 0.07	0.75 ± 0.04	0.77 ± 0.06	0.74 ± 0.05	0.74 ± 0.04	0.18 ± 0.01	154/303
		Internal validation	0.78	0.71	0.71	0.78	0.64	0.69	0.19	63/131
		External validation	0.81	0.4	0.4	0.73	0.28	0.72	0.18	45/334
	GradientBoostingClassifi er	Cross-validation	0.83 ± 0.07	0.81 ± 0.08	0.76 ± 0.08	0.75 ± 0.06	0.77 ± 0.12	0.75 ± 0.09	0.2 ± 0.06	154/303
		Internal validation	0.78	0.72	0.63	0.6	0.67	0.66	0.27	63/131
		External validation	0.76	0.33	0.35	0.58	0.25	0.66	0.24	45/334
	RandomForestClassifier	Cross-validation	0.81 ± 0.02	0.8 ± 0.05	0.74 ± 0.04	0.77 ± 0.07	0.72 ± 0.05	0.73 ± 0.04	0.2 ± 0.0	154/303
		Internal validation	0.78	0.75	0.71	0.73	0.69	0.71	0.21	63/131
		External validation	0.8	0.37	0.4	0.76	0.27	0.72	0.21	45/334
	XGBClassifier	Cross-validation	0.82 ± 0.05	0.82 ± 0.07	0.74 ± 0.07	0.73 ± 0.1	0.75 ± 0.05	0.74 ± 0.06	0.17 ± 0.03	154/303
		Internal validation	0.79	0.73	0.69	0.7	0.68	0.69	0.19	63/131
		External validation	0.78	0.35	0.42	0.69	0.3	0.72	0.17	45/334
	ExtraTreesClassifier	Cross-validation	0.84 ± 0.04	0.82 ± 0.08	0.78 ± 0.01	0.81 ± 0.05	0.76 ± 0.06	0.77 ± 0.02	0.18 ± 0.01	154/303
		Internal validation	0.77	0.74	0.68	0.71	0.65	0.68	0.2	63/131
		External validation	0.77	0.31	0.36	0.67	0.25	0.68	0.19	45/334
Gaussian	GaussianProcessClassifi	Cross-validation	0.53 ± 0.1	0.55 ± 0.13	0.4 ± 0.09	0.34 ± 0.09	0.49 ± 0.11	0.49 ± 0.07	0.25 ± 0.0	154/303
process	er	Internal validation	0.6	0.54	0.47	0.43	0.53	0.54	0.25	63/131
		External validation	0.54	0.14	0.2	0.38	0.14	0.51	0.25	45/334
Linear	LogisticRegression	Cross-validation	0.72 ± 0.11	0.73 ± 0.11	0.7 ± 0.1	0.72 ± 0.1	0.68 ± 0.12	0.68 ± 0.11	0.22 ± 0.04	154/303
models		Internal validation	0.65	0.65	0.61	0.68	0.56	0.59	0.24	63/131
		External validation	0.66	0.23	0.33	0.58	0.23	0.64	0.21	45/334
	PassiveAggressiveClassi	Cross-validation	0.71 ± 0.11	0.69 ± 0.12	0.29 ± 0.4	0.27 ± 0.41	0.53 ± 0.52	0.56 ± 0.13	0.31 ± 0.12	154/303
	fier	Internal validation	0.65	0.59	0.64	0.98	0.48	0.49	0.45	63/131
		External validation	0.71	0.32	0.08	0.04	0.67	0.52	0.11	45/334
	SGDClassifier	Cross-validation	0.56 ± 0.09	0.54 ± 0.05	0.4 ± 0.46	0.48 ± 0.55	0.35 ± 0.4	0.56 ± 0.09	0.44 ± 0.09	154/303
		Internal validation	0.53	0.5	0.62	0.83	0.5	0.53	0.48	63/131
	_	External validation	0.54	0.15	0.24	0.58	0.15	0.54	0.48	45/334
	Perceptron	Cross-validation	0.55 ± 0.05	0.6 ± 0.07	0.39 ± 0.35	0.47 ± 0.55	0.54 ± 0.09	0.5 ± 0.03	0.33 ± 0.07	154/303
		Internal validation	0.55	0.62	0.03	0.02	1	0.51	0.45	63/131
		External validation	0.55	0.16	0.21	0.38	0.15	0.52	0.26	45/334
Naïve	GaussianNB	Cross-validation	0.79 ± 0.06	0.77 ± 0.07	0.73 ± 0.04	0.7 ± 0.03	0.76 ± 0.05	0.73 ± 0.04	0.25 ± 0.03	154/303

Bayes Internal validation 0.75 0.72 0.69 0.71 0.66 0.69 0.28 63/131 Nearest KNeighborsClassifier Cross-validation 0.73 0.25 0.65 0.66 0.27 45/334 Nearest KNeighborsClassifier Cross-validation 0.59 ± 0.09 0.6 ± 0.08 0.59 ± 0.04 0.58 ± 0.07 0.62 0.64 0.22 63/131 Neighbor Internal validation 0.68 0.66 0.63 0.63 0.62 0.64 0.22 63/131 Support LinearSVC Cross-validation 0.69 ± 0.11 0.73 ± 0.1 0.66 ± 0.05 0.83 ± 0.24 0.57 ± 0.11 0.57 ± 0.07 0.29 ± 0.11 154/303 vector Internal validation 0.62 0.61 0.64 0.98 0.48 0.49 0.47 63/131 machine External validation 0.72 0.67 0.64 0.69 0.67 0.24 63/131 Tree based DecisionTreeClassifier Cross-validation 0.72 </th <th>Davias</th> <th></th> <th>Latence Latence Cateron</th> <th>0.75</th> <th>0.70</th> <th>0.00</th> <th>0.74</th> <th>0.00</th> <th>0.00</th> <th>0.00</th> <th>00/404</th>	Davias		Latence Latence Cateron	0.75	0.70	0.00	0.74	0.00	0.00	0.00	00/404
Nearest Neighbor KNeighborsClassifier Cross-validation 0.59 ± 0.09 0.6 ± 0.08 0.59 ± 0.04 0.58 ± 0.07 0.6 ± 0.07 0.59 ± 0.05 0.25 ± 0.02 154/303 Support vector machine LinearSVC Cross-validation 0.61 0.21 0.27 0.53 0.18 0.58 0.23 45/334 Tree based DecisionTreeClassifier Cross-validation 0.69 ± 0.11 0.73 ± 0.1 0.66 ± 0.05 0.83 ± 0.24 0.57 ± 0.11 0.57 ± 0.07 0.29 ± 0.11 154/303 Tree based DecisionTreeClassifier Cross-validation 0.67 0.34 0.09 0.04 1 0.52 0.11 45/334 Discrimina nt analysis LinearDiscriminantAnalys Cross-validation 0.72 0.67 0.64 0.62 0.67 0.67 0.22 0.34 Neighbors LinearDiscriminantAnalys LinearDiscriminantAnalys Cross-validation 0.72 0.67 0.64 0.62 0.67 0.67 0.22 0.34 Number LinearDiscriminantAnalys LinearDiscrim	Bayes		Internal validation	0.75	0.72	0.69	0.71	0.66	0.69	0.28	63/131
Neighbor Internal validation 0.68 0.66 0.63 0.63 0.62 0.64 0.22 63/131 Support vector machine LinearSVC Cross-validation 0.61 0.21 0.27 0.53 0.18 0.58 0.23 45/334 Support vector machine LinearSVC Cross-validation 0.69 ± 0.11 0.73 ± 0.1 0.66 ± 0.05 0.83 ± 0.24 0.57 ± 0.11 0.57 ± 0.07 0.29 ± 0.11 154/303 Tree based DecisionTreeClassifier Cross-validation 0.67 0.34 0.09 0.04 1 0.52 0.11 45/334 Discrimina nt analysis DecisionTreeClassifier Cross-validation 0.72 0.67 0.64 0.62 0.67 0.67 0.24 63/131 Discrimina nt analysis LinearDiscriminantAnalys Cross-validation 0.72 0.67 0.64 0.62 0.67 0.66 0.76 ± 0.05 0.18 ± 0.04 154/303 Discrimina nt analysis LinearDiscriminantAnalys Cross-validation 0.74 0.72 0			External validation	0.73	0.25	0.35	0.6	0.25	0.66	0.27	45/334
Support vector LinearSVC Cross-validation 0.61 0.21 0.27 0.53 0.18 0.58 0.23 45/334 Support vector LinearSVC Cross-validation 0.69 ± 0.11 0.73 ± 0.1 0.66 ± 0.05 0.83 ± 0.24 0.57 ± 0.11 0.57 ± 0.07 0.29 ± 0.11 154/303 machine Internal validation 0.62 0.61 0.64 0.98 0.48 0.49 0.47 63/131 machine External validation 0.72 0.67 0.64 0.98 0.48 0.49 0.47 63/131 Tree based DecisionTreeClassifier Cross-validation 0.72 ± 0.08 0.67 ± 0.04 0.63 ± 0.06 0.72 ± 0.09 0.68 ± 0.05 0.22 ± 0.04 154/303 Discrimina nt analysis LinearDiscriminantAnalys Cross-validation 0.72 0.67 0.65 0.65 0.66 0.22 45/334 Discrimina nt analysis LinearDiscriminantAnalysis Internal validation 0.74 0.72 0.65 0.65 0.66 0.26 63/131	Nearest	KNeighborsClassifier	Cross-validation	0.59 ± 0.09	0.6 ± 0.08	0.59 ± 0.04	0.58 ± 0.07	0.6 ± 0.07	0.59 ± 0.05	0.25 ± 0.02	154/303
	Neighbor		Internal validation	0.68	0.66	0.63	0.63	0.62	0.64	0.22	63/131
vector machine Internal validation 0.62 0.61 0.64 0.98 0.48 0.49 0.47 63/131 machine External validation 0.7 0.34 0.09 0.04 1 0.52 0.11 45/334 Tree based DecisionTreeClassifier Cross-validation 0.75 ± 0.08 0.72 ± 0.08 0.67 ± 0.04 0.63 ± 0.06 0.72 ± 0.09 0.68 ± 0.05 0.22 ± 0.04 154/303 Discrimina nt analysis LinearDiscriminantAnalys is Cross-validation 0.72 0.67 0.64 0.62 0.67 0.67 0.24 63/131 Use Cross-validation 0.72 0.67 0.64 0.62 0.67 0.67 0.24 63/131 Discrimina nt analysis LinearDiscriminantAnalys is Cross-validation 0.74 0.72 0.65 0.65 0.65 0.65 0.65 0.65 0.65 0.65 0.65 0.65 0.66 0.22 45/334 Discrimina nt analysis QuadraticDiscriminantAn alysis Cross-validation			External validation	0.61	0.21	0.27	0.53	0.18	0.58	0.23	45/334
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	Support	LinearSVC	Cross-validation	0.69 ± 0.11	0.73 ± 0.1	0.66 ± 0.05	0.83 ± 0.24	0.57 ± 0.11	0.57 ± 0.07	0.29 ± 0.11	154/303
Tree based basedDecisionTreeClassifierCross-validation Internal validation 0.75 ± 0.08 0.72 ± 0.08 0.67 ± 0.04 0.63 ± 0.06 0.72 ± 0.09 0.68 ± 0.05 0.22 ± 0.04 $154/303$ Discrimina nt analysisLinearDiscriminantAnalys isLinearDiscriminantAnalys isLinearDiscriminantAnalys isCross-validation 0.74 0.72 0.67 0.64 0.62 0.67 0.67 0.67 0.24 $63/131$ QuadraticDiscriminantAn alysisLinearDiscriminantAn isCross-validation 0.74 0.72 0.65 0.65 0.65 0.66 0.26 ± 0.05 0.18 ± 0.04 $154/303$ QuadraticDiscriminantAn alysisCross-validation 0.74 0.72 0.65 0.65 0.65 0.66 $0.26 \pm 63/131$ DiscriminantAn alysisCross-validation 0.74 0.72 0.65 0.65 0.65 0.66 $0.26 \pm 63/131$ DiscriminantAn alysisCross-validation 0.74 0.72 0.65 0.65 0.65 0.66 0.26 ± 0.04 $154/303$ DiscriminantAn alysisCross-validation 0.76 ± 0.08 0.74 ± 0.11 0.72 ± 0.07 0.71 ± 0.13 0.74 ± 0.05 0.22 ± 0.04 $154/303$ DiscriminantAn alysisCross-validation 0.77 ± 0.08 0.71 ± 0.07 0.76 0.71 ± 0.76 0.66 0.77 ± 0.05 0.26 ± 0.04 $154/303$ DiscriminantAn alysisCross-validation 0.77 ± 0.76 0.71 ± 0.76 0.66	vector		Internal validation	0.62	0.61	0.64	0.98	0.48	0.49	0.47	63/131
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	machine		External validation	0.7	0.34	0.09	0.04	1	0.52	0.11	45/334
Discrimina nt analysis LinearDiscriminantAnalys is External validation 0.7 0.22 0.34 0.58 0.24 0.65 0.25 45/334 Discrimina nt analysis LinearDiscriminantAnalys is Cross-validation 0.85 ± 0.05 0.85 ± 0.06 0.77 ± 0.04 0.79 ± 0.05 0.75 ± 0.06 0.76 ± 0.05 0.18 ± 0.04 154/303 QuadraticDiscriminantAn alysis QuadraticDiscriminantAn internal validation 0.74 0.72 0.65 0.65 0.65 0.66 0.26 63/131 QuadraticDiscriminantAn alysis Cross-validation 0.76 ± 0.08 0.74 ± 0.11 0.72 ± 0.07 0.71 ± 0.13 0.74 ± 0.05 0.72 ± 0.05 0.26 ± 0.04 154/303 Internal validation 0.76 ± 0.08 0.74 ± 0.11 0.72 ± 0.07 0.71 ± 0.13 0.74 ± 0.05 0.72 ± 0.05 0.26 ± 0.04 154/303 Internal validation 0.77 0.76 0.71 0.76 0.66 0.7 0.27 63/131 Internal validation 0.77 0.23 0.35 0.67 0.24 0.67 0.3 <	Tree based	d DecisionTreeClassifier	Cross-validation	0.75 ± 0.08	0.72 ± 0.08	0.67 ± 0.04	0.63 ± 0.06	0.72 ± 0.09	0.68 ± 0.05	0.22 ± 0.04	154/303
Discrimina nt analysis LinearDiscriminantAnalys is Cross-validation 0.85 ± 0.05 0.85 ± 0.06 0.77 ± 0.04 0.79 ± 0.05 0.75 ± 0.06 0.76 ± 0.05 0.18 ± 0.04 154/303 nt analysis Internal validation 0.74 0.72 0.65 0.65 0.65 0.66 0.26 63/131 QuadraticDiscriminantAn alysis Cross-validation 0.81 0.34 0.45 0.78 0.32 0.76 0.2 45/334 QuadraticDiscriminantAn alysis Cross-validation 0.76 ± 0.08 0.74 ± 0.11 0.72 ± 0.07 0.71 ± 0.13 0.74 ± 0.05 0.72 ± 0.05 0.26 ± 0.04 154/303 Linernal validation 0.77 0.76 0.71 0.76 0.66 0.7 0.26 ± 0.04 154/303 Linernal validation 0.77 0.76 0.71 0.76 0.66 0.7 0.27 63/131			Internal validation	0.72	0.67	0.64	0.62	0.67	0.67	0.24	63/131
Int analysis is Internal validation External validation 0.74 0.72 0.65 0.65 0.66 0.26 63/131 QuadraticDiscriminantAn alysis Cross-validation 0.81 0.34 0.45 0.78 0.32 0.76 0.2 45/334 Internal validation 0.76 ± 0.08 0.74 ± 0.11 0.72 ± 0.07 0.71 ± 0.13 0.74 ± 0.05 0.72 ± 0.05 0.26 ± 0.04 154/303 Internal validation 0.77 0.76 0.71 0.76 0.66 0.7 0.27 63/131 External validation 0.77 0.76 0.71 0.76 0.66 0.7 0.27 63/131			External validation	0.7	0.22	0.34	0.58	0.24	0.65	0.25	45/334
External validation 0.81 0.34 0.45 0.78 0.32 0.76 0.2 45/334 QuadraticDiscriminantAn alysis Cross-validation 0.76 ± 0.08 0.74 ± 0.11 0.72 ± 0.07 0.71 ± 0.13 0.74 ± 0.05 0.72 ± 0.05 0.26 ± 0.04 154/303 Internal validation 0.77 0.76 0.71 0.76 0.66 0.7 0.27 63/131 External validation 0.77 0.23 0.35 0.67 0.24 0.67 0.3 45/334	Discrimina	LinearDiscriminantAnalys	Cross-validation	0.85 ± 0.05	0.85 ± 0.06	0.77 ± 0.04	0.79 ± 0.05	0.75 ± 0.06	0.76 ± 0.05	0.18 ± 0.04	154/303
QuadraticDiscriminantAn alysis Cross-validation 0.76 ± 0.08 0.74 ± 0.11 0.72 ± 0.07 0.71 ± 0.13 0.74 ± 0.05 0.72 ± 0.05 0.26 ± 0.04 154/303 Internal validation 0.77 0.76 0.71 0.76 0.66 0.7 0.27 63/131 External validation 0.7 0.23 0.35 0.67 0.24 0.67 0.3 45/334	nt analysis	is	Internal validation	0.74	0.72	0.65	0.65	0.65	0.66	0.26	63/131
alysis Internal validation 0.77 0.76 0.71 0.76 0.66 0.7 0.27 63/131 External validation 0.7 0.23 0.35 0.67 0.24 0.67 0.3 45/334			External validation	0.81	0.34	0.45	0.78	0.32	0.76	0.2	45/334
External validation 0.7 0.23 0.35 0.67 0.24 0.67 0.3 45/334		QuadraticDiscriminantAn	Cross-validation	0.76 ± 0.08	0.74 ± 0.11	0.72 ± 0.07	0.71 ± 0.13	0.74 ± 0.05	0.72 ± 0.05	0.26 ± 0.04	154/303
		alysis	Internal validation	0.77	0.76	0.71	0.76	0.66	0.7	0.27	63/131
Neural MLPClassifier Cross-validation 0.72 ± 0.11 0.72 ± 0.14 0.71 ± 0.06 0.82 ± 0.08 0.64 ± 0.09 0.66 ± 0.09 0.29 ± 0.09 154/303			External validation	0.7	0.23	0.35	0.67	0.24	0.67	0.3	45/334
	Neural	MLPClassifier	Cross-validation	0.72 ± 0.11	0.72 ± 0.14	0.71 ± 0.06	0.82 ± 0.08	0.64 ± 0.09	0.66 ± 0.09	0.29 ± 0.09	154/303
network Internal validation 0.72 0.72 0.68 0.94 0.54 0.59 0.38 63/131	network		Internal validation	0.72	0.72	0.68	0.94	0.54	0.59	0.38	63/131
External validation 0.71 0.29 0.3 0.87 0.18 0.63 0.46 45/334			External validation	0.71	0.29	0.3	0.87	0.18	0.63	0.46	45/334

447







Figure 2














Ε.










Use of ventilator GFR less than 60 ml/min/1.72m2 Potassium Age group: 80-89 Age group: 90+ Alanine aminotransferase White blood cells First heart rate Procalcitonin First respiratory rate C-reactive protein History of congestive heart failure Lymphocytes Sodium Hemoglobin Age group: 70-79 Blood glucose level History of dementia Neutrophils On anticoagulant

Model type

RandomForest model for predicting ICU admission



C-reactive protein Procalcitonin Lactate dehydrogenase Lymphocytes Neutrophils First oxygen saturation First respiratory rate Calcium Ferritin Alanine aminotransferase Sodium Hemoglobin Chloride Blood glucose level White blood cells First heart rate Anion gap D-dimer Female gender

XGBoost model for predicting death

